Targeting H3K4 trimethylation in Huntington disease.

Vashishtha M, Ng CW, Yildirim F, Gipson TA, Kratter IH, Bodai L, Song W, Lau A, Labadorf A, Vogel-Ciernia A, Troncosco J, Ross CA, Bates GP, Krainc D, Sadri-Vakili G, Finkbeiner S, Marsh JL, Housman D

Proc Natl Acad Sci U S A. 2013 Aug 6;110(32):E3027-36. doi: 10.1073/pnas.1311323110.

Treatment of psychotic and behavioral symptoms with clozapine, aripiprazole, and reboxetine in a patient with Huntington's disease.

Edlinger M, Seppi K, Fleischhacker W, Hofer A.

Int Clin Psychopharmacol. 2013 Jul;28(4):214-6. doi: 10.1097/YIC.0b013e328361e145.

Increased 5-methylcytosine and decreased 5-hydroxymethylcytosine levels are associated with reduced striatal A2AR levels in Huntington's disease.

Villar-Menéndez I, Blanch M, Tyebji S, Pereira-Veiga T, Albasanz JL, Martín M, Ferrer I, Pérez-Navarro E, Barrachina M.

Neuromolecular Med. 2013 Jun;15(2):295-309. doi: 10.1007/s12017-013-8219-0.

Chorea in systematic lupus erythematosus; a case report.

Ueda Y, Takahashi Y, Yamashita H, Kano T, Mimori A.

Nihon Rinsho Meneki Gakkai Kaishi. 2013;36(6):467-72.

Cognitive reserve and brain reserve in prodromal Huntington's disease.

Bonner-Jackson A, Long JD, Westervelt H, Tremont G, Aylward E, Paulsen JS; PREDICT-HD Investigators and Coordinators of the Huntington Study Group..

J Int Neuropsychol Soc. 2013 Aug;19(7):739-50. doi: 10.1017/S1355617713000507.

Effects of a One Year Intensive Multidisciplinary Rehabilitation Program for Patients with Huntington's Disease: a Prospective Intervention Study.

Piira A, van Walsem MR, Mikalsen G, Nilsen KH, Knutsen S, Frich JC.

PLoS Curr. 2013 Sep 20;5. pii: ecurrents.hd.9504af71e0d1f87830c25c394be47027. doi: 10.1371/currents.hd.9504af71e0d1f87830c25c394be47027.

Cerebellar contribution to anger recognition deficits in Huntington's disease.

Scharmüller W, Ille R, Schienle A.

Cerebellum. 2013 Dec;12(6):819-25. doi: 10.1007/s12311-013-0492-9.

Huntington disease: How many repeats does it take?

Hogarth P.

Neurology. 2013 May 28;80(22):e241-3. doi: 10.1212/WNL.0b013e3182984b31. No abstract available.

Epigenetic regulation of cholinergic receptor M1 (CHRM1) by histone H3K9me3 impairs Ca(2+) signaling in Huntington's disease.

Lee J, Hwang YJ, Shin JY, Lee WC, Wie J, Kim KY, Lee MY, Hwang D, Ratan RR, Pae AN, Kowall NW, So I, Kim JI, Ryu H.

Acta Neuropathol. 2013 May;125(5):727-39. doi: 10.1007/s00401-013-1103-z.

Episodic memory decline in Huntington's disease, a binding deficit?

El Haj M, Caillaud M, Fasotti L, Verny C, Allain P.

J Huntingtons Dis. 2013;2(3):305-13. doi: 10.3233/JHD-130056.

Chorea and retinal vessel occlusion in a patient with systemic lupus erythematosus.

Ostovan VR, Ghorbani A.

Iran J Neurol. 2013;12(2):66-8.

Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the Guideline Development Subcommittee of the American Academy of Neurology.

Suchowersky O, Armstrong MJ, Miyasaki J.

Neurology. 2013 Mar 5;80(10):970. doi: 10.1212/WNL.0b013e3182885eb3. No abstract available.

Default-mode network changes in Huntington's disease: an integrated MRI study of functional connectivity and morphometry.

Quarantelli M, Salvatore E, Giorgio SM, Filla A, Cervo A, Russo CV, Cocozza S, Massarelli M, Brunetti A, De Michele G.

PLoS One. 2013 Aug 19;8(8):e72159. doi: 10.1371/journal.pone.0072159.

Surveying the landscape of Huntington's disease mechanisms, measurements, and medicines.

Crook ZR, Housman DE.

J Huntingtons Dis. 2013;2(4):405-36. doi: 10.3233/JHD-130072. Review.

Aberrantly spliced HTT, a new player in Huntington's disease pathogenesis.

Gipson TA, Neueder A, Wexler NS, Bates GP, Housman D.

RNA Biol. 2013 Nov;10(11):1647-52. doi: 10.4161/rna.26706.